Chronic Lymphocytic Leukemia | Specialty

Dr. Epperla on the Implications of an FDA Approval for Ublituximab/Umbralisib in CLL

June 12th 2021

Narendranath Epperla, MD, MS, discusses the implications of a potential FDA approval for the combination of ublituximab and umbralisib for patients with chronic lymphocytic leukemia.

Zanubrutinib Demonstrates Impressive Responses in Relapsed/Refractory CLL

June 11th 2021

Zanubrutinib continued to induce deep responses with acceptable tolerability in patients with relapsed/refractory chronic lymphocytic leukemia, including those with high-risk cytogenetics.

Dr. Barr on the Next Steps of the RESONATE-2 Trial in CLL

June 11th 2021

Paul M. Barr, MD, discusses the next steps of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Dr. Hillmen on Results With Acalabrutinib in CLL

June 11th 2021

Peter Hillmen, MD, PhD, discusses results reported with acalabrutinib in patients with chronic lymphocytic leukemia, as demonstrated in a phase 3 trial.

Fixed-Dose Venetoclax/Obinutuzumab Combo Maintains PFS Benefit at 3 Years Following Treatment Cessation

June 11th 2021

The fixed-dose combination of the BCL-2 inhibitor venetoclax and the humanized anti-CD20 monoclonal antibody obinutuzumab continued to confer a progression-free survival advantage over chlorambucil plus obinutuzumab for patients with previously untreated chronic lymphocytic leukemia.

Dr. Al-Sawaf on the Efficacy of Venetoclax/Obinutuzumab in Treatment-Naïve CLL

June 11th 2021

Othman Al-Sawaf, MD, discusses the efficacy of venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia, as demonstrated in the phase 3 CLL14 trial.

Zanubrutinib May Be Superior to Ibrutinib in Relapsed/Refractory CLL/SLL

June 11th 2021

Zanubrutinib induced superior response and progression-free survival rates, as well as lower rates of atrial fibrillation/flutter than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Dr. Byrd on the Rationale for the ELEVATE-RR Trial in CLL

June 10th 2021

John C. Byrd, MD, discusses the rationale for the phase 3 ELEVATE-RR trial in chronic lymphocytic leukemia.

Dr. Ailawadhi on the Rationale to Evaluate Lisaftoclax in CLL

June 9th 2021

Sikander Ailawadhi, MD, discusses the rationale to evaluate lisaftoclax in chronic lymphocytic leukemia.

Duvelisib Approved in Europe for Relapsed/Refractory CLL or Follicular Lymphoma

June 9th 2021

The European Medicines Agency has granted marketing authorization to duvelisib for single-agent use in patients with relapsed/refractory chronic lymphocytic leukemia who have previously received at least 2 therapies or those with follicular lymphoma whose disease is refractory to at least 2 previous systemic therapies.

First-Line Ibrutinib/Venetoclax Inhibits Response in CLL/SLL

June 7th 2021

Ibrutinib plus venetoclax produced a complete response and complete response with incomplete bone marrow recovery rate of 56% in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Lisaftoclax Shows Early Safety, Efficacy in Relapsed/Refractory CLL/SLL and Other Hematologic Cancers

June 7th 2021

The novel BCL-2 inhibitor lisaftoclax elicited encouraging responses with acceptable tolerability in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and other hematologic cancers.

Acalabrutinib is Better Tolerated, Noninferior to Ibrutinib in Previously Treated CLL

June 7th 2021

Single Agent and Combination TG-1701 Yield Promising Clinical Activity in CLL and Other B-Cell Malignancies

June 5th 2021

TG-1701 demonstrated encouraging clinical and pharmacodynamic activity at all dose levels in patients with B-cell malignancies.

First-Line Ibrutinib Yields 7-Year Survival Benefit in CLL

June 5th 2021

Single-agent ibrutinib given in the first-line setting sustained a progression-free survival and overall survival benefit compared with chlorambucil as therapy for patients with chronic lymphocytic leukemia at 7-year follow-up.

Cirmtuzumab Plus Ibrutinib Had Overall Response Rates in MCL and CLL

June 4th 2021

Cirmtuzumab and ibrutinib led to reported high overall response rates in patients with mantle cell lymphoma or chronic lymphocytic leukemia.

Dr. Abedin on the Need for Risk Stratification Before Chemoimmunotherapy in CLL

June 3rd 2021

Sameem Abedin, MD, discusses the need for risk stratification prior to giving chemoimmunotherapy to patients with chronic lymphocytic leukemia.

Single-Hit TP53 Associated With Prolonged OS and PFS Vs Multi-Hit TP53 in Ibrutinib-Treated CLL

May 27th 2021

Patients with chronic lymphocytic leukemia and single-hit TP53 mutations derived long-term responses with ibrutinib monotherapy, whereas patients with multi-hit TP53 aberrations had shortened progression-free survival.

OS and Time to Richter Transformation Linked With Age in Adolescent and Young Adults With CLL

May 26th 2021

Age was associated with overall survival and the time to Richter transformation in adolescent and young adult patients with chronic lymphocytic leukemia, according to findings from a single-institutional, retrospective study.

Ibrutinib Plus Venetoclax Results in High Residual Disease Eradication in CLL Model

May 17th 2021

The combination of ibrutinib and venetoclax were found to act on distinct subpopulations of chronic lymphocytic leukemia that have different proliferative capacities in an ex vivo model of the disease, suggesting that the dual-targeted approach has the potential to eradicate residual disease in patients with CLL.